GABRIELLE UPTON:
NSW leads the nation with $180 billion invested by the state government since 2011 in ‘hard’ infrastructure like roads, transport, hospitals and schools. It is a once in a lifetime investment delivering a better quality of life for all our citizens.
At the same time, the NSW Government has a bold ambition investing in ideas, ‘soft’ infrastructure, to accelerate R&D commercialisation. The long term benefits from this type of investment are large through the creation of jobs and new industries and boosting long term economic growth. For communities it means new products and services including better health treatments, safer transport services and solutions for water and energy sustainability. The Government is uniquely placed to invest in R&D commercialisation because its long term, patient capital is an indispensable ingredient for success.
NSW has a clear head start with more top universities, start-ups and a larger skilled workforce than any other Australian jurisdiction. Our state has specific R&D strengths like quantum computing, robotics, material sciences and medical technology and a track record of inventions with global impact such as the electronic pacemaker, the Google Maps platform and autonomous vehicle navigation for mines and ports. Our attractiveness has led to industry investing more in R&D in NSW than any other jurisdiction in Australia.
With the 2021 launch of the “Turning Ideas into Jobs” Accelerating R&D in NSW Action Plan our state has the blueprint for success. The Action Plan was guided by an advisory council of eminent leaders, chaired by David Gonski, in consultation with research organisations, industry, start-ups, scale-ups and universities. It delivers a strategy, a plan for execution, a ministry and a department and now commands a substantial budget.
With $500 million invested through the action plan the initiatives have world class breadth and depth. We are centralising our activities in our innovation precincts, launching R&D missions aimed at solving long-term strategic challenges for the state, like improving our bushfire response, and using the government’s $30 billion procurement budget to drive innovative solutions to government agency problems. Our ‘first in nation’ 20-year R&D Roadmap identifies NSW’s research and industry competitive advantages and guides our investments and activities.
The action plan has a strong focus on supporting R&D commercialisation pathways and builds on our historical pocket of translational excellence: the NSW Medical Devices Fund (MDF). Launched in 2013, the MDF helps commercialise medical devices typically between Technology Readiness Level scale ‘three’ (proof-of-concept model) and ‘seven’ (workable model). Over $78 million has been awarded in MDF grants to 43 technologies with organisations raising more than $810 million. Over 250 patents have been awarded and there has been an over two-fold increase in employment for grant recipients. Examples of potentially life changing funded projects include an affordable dialysis system, a treatment for chronic pain and kits for scalable gene delivery which are important for gene therapies helping cure forms of cancer.
The success of this commercialisation pathway model comes from its design—it is focused, holistic and intensive. It supports promising technologies with sizeable grants through the so-called ‘valley of death’ where private capital is scarce. The founders benefit by retaining their equity and are able to concentrate on developing their ideas, rather than on fundraising. They also receive mentoring, expert panel reviews, and training and development. Grant funding decisions are based on clinicians’ assessments of the whole supply chain and the market attractiveness of the technology. The government’s funding pool is also optimised because the recipient repays the grant when the commercialisation of an invention reaches an agreed level of profitability.
To see how the right support at the right time increases R&D commercialisation success we need to look no further than NSW-based company SpeeDx, a twice-MDF grant recipient. SpeeDx was founded by two female scientists turned entrepreneurs (Adjunct Professor Alison Todd and Dr Elisa Mokany) and won the 2022 Prime Minister’s Prize for Innovation for commercialising and worldwide distribution of their innovative molecular diagnostic tests for infectious diseases and cancer.
CleanSpace, another MDF recipient, now designs, manufactures and sells high level respiratory protection equipment into international healthcare and industrial markets. Off the back of this successful model, the NSW Government has adopted the commercialisation pathway model in other sectors – the $10 million Physical Sciences Fund (PSF) and the $7 million Quantum Computing Commercialisation Fund. The Yield Technology Solutions, for example, is one of the 2022 PSF recipients. The company will develop scalable digital technology to reduce the impacts of weather uncertainty on waste across the food supply chain.
Successful R&D commercialisation creates jobs, new services and products and industries—things that all governments aspire to help deliver. Thanks to the NSW Government, our state is the national leader and a world-class contributor to research translation and commercialisation. This bold ambition is being realised through the execution of a focused and well-resourced strategy.
At the time of writing, The Hon Gabrielle Upton MP was Parliamentary Secretary to the NSW Premier.